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ABSTRACT  
Background: Critically ill patients often present increased insulin resistance and stress-induced 
hyperglycemia. Tight glycemic control aims to reduce blood glucose (BG) levels and variability while 
ensuring safety from hypoglycemia. This paper presents the results of the second Belgian clinical trial 
using the customizable STAR framework in a target-to-range control approach. The main objective is 
reducing measurement frequency while maintaining performance and safety of the glycemic control. 
Methods: The STAR-Liege 2 (SL2) protocol targeted the 100-140 mg/dL glycemic band and offered 
2-hourly and 3-hourly interventions. Only insulin rates were adjusted, and nutrition inputs were left to 
the attending clinicians. This protocol restricted the forecasted risk of BG < 90 mg/dL to a 5% level 
using a stochastic model of insulin sensitivity to assess patient-specific responses to insulin and its 
future likely variability to optimize insulin interventions. The clinical trial was performed at the Centre 
Hospitalier Universitaire de Liege and included 9 patients. Results are compared to 24-hour pre-trial 
and 24-hour post-trial, but also to the results of the first pilot trial performed in Liege, STAR-Liege 1 
(SL1). This trial was approved by the Ethics Committee of the Medical Faculty of the University of 
Liege (Liege, Belgium). 
Results: During the SL2 trial, 91 measurements were taken over 194 hours. BG levels were tightly 
distributed: 54.9% of BG within 100-140 mg/dL, 40.7% were ≥ 140 mg/dL and 4.4% were < 100 
mg/dL with no BG < 70 mg/dL. Comparing these results with 24-hour pre-trial and post-trial shows 
that SL2 reduced high and low BG levels and reduced glycemic variability. Nurses selected 3-hourly 
measurement only 5 of 16 times and overrode 12% of 91 recommended interventions (35% increased 
insulin rates and 65% decreased insulin rates). SL1 and SL2 present similar BG levels distribution (p > 
0.05) with significantly reduced measurement frequency for SL2 (p < 0.05). 
Conclusions: The SL2 protocol succeeded in reducing clinical workload while maintaining safety and 
effectiveness of the glycemic control. SL2 was also shown to be safer and tighter than hospital control. 
Overall results validate the efficacy of significantly customizing the STAR framework. 
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1. BACKGROUND 
In critically ill patients, increased insulin resistance due to stress results in stress-induced 
hyperglycemia, which is linked to worsened patient outcomes and increased mortality [1-4]. Tight 
glycemic control (TGC) seeks to reduce the blood glucose (BG) levels and variability associated with 
negative outcomes, and can reduce mortality up to 45% [5-7]. However, a high risk of hypoglycemia 
and inability to repeat successful results have been associated with many TGC protocols [8], where 
limiting low BG levels is crucial to ensure control safety [3, 9, 10]. 
High inter- and intra- patient variability makes successful TGC difficult [11-13]. Model-based 
controllers use computer models of patient physiology to capture patient-specific response to insulin 
and nutrition inputs. Thus, they enable TGC protocols to predict patient response to optimize 
interventions and resulting BG levels in the presence of variability [14-17].  
STAR (Stochastic TARgeted) is a flexible model-based control approach that enables adaptive, 
patient-specific TGC. STAR directly accounts for evolving physiological patient condition and inter- 
and intra- patient variability by identifying insulin sensitivity (SI) and its future variability [11] at each 
intervention to optimize control and safety. STAR can be customized for clinically specified glycemic 
targets, control approaches (e.g. insulin only, insulin and nutrition, etc.) and clinical resources (e.g. 
measurement frequency).  
The STAR framework was previously customized in glycemic target and control intervention to match 
clinical standards at the Centre Hospitalier Universitaire (CHU) of Liege, Belgium [18]. This paper 
presents a significantly modified and improved STAR-Liege protocol, based on issues highlighted in 
the first pilot trial results. In particular, only 2 and 3 hourly insulin interventions were offered. The 
goal was changed to maximize the overlap of the potential (5th-95th percentile) glycemic outcome 
range with a clinically specified 100-140 mg/dL band, a target-to-range approach. In contrast, the prior 
approach had a specific target (125 mg/dL) and offered 1-hourly interventions that resulted in 20-24 
measurements per day. Finally, the stochastic models were updated to better account for the more 
variable cardiovascular surgery patient cohort in this intensive care unit (ICU), where recent studies 
found these patients to be more insulin resistant and variable (greater intra-patient variability), 
especially for the first days of ICU stay than the overall medical ICU cohort as a whole [13]. Hence, 
the stochastic model used here directly accounted for this variability by using clinical data specific to 
cardiac-surgery patients and for the first days of stay. The main objective of these second clinical trials 
was reducing clinical workload for a highly variable ICU cohort, while maintaining control quality 
and safety, by using a target-to-range approach. 
  
2. METHOD 
2.1. STAR-Liege 2 Protocol  
Three major changes were made for the STAR-Liege 2 (SL2) protocol. First, the clinically specified 
glycemic target of 125 mg/dL was changed to a target band (100-140 mg/dL). Second, measurement 
frequency was reduced, and only 2-hourly and 3-hourly interventions were used to reduce workload. 
These intervals allowed insulin infusions sufficient time to act so that the controller could more 
accurately identify insulin action. Finally, the SL2 protocol differed from the SL1 in that it did not 
specify any nutrition whatsoever. During the SL1 pilot trial, nutrition administration was generally left 
to the attending clinician who had to enter nutrition rates (and their changes) into the controller to 
account for the patient feeding. However, the SL1 protocol did recommended increased nutrition rates 
at low BG concentrations, to prevent unintended hypoglycemia. The SL2 protocol removed these 
recommendations, making the controller more simple and transparent. An improved glucose-insulin 
system model was also used (denoted ICING-2 [19]) and described in the Appendix. The four main 
steps of the new SL2 protocol are illustrated in Figure 1. They are described in detail below: 
1. Previous and current BG measurements and clinical data (nutrition and insulin rates) are used 
to identify the current patient-specific model-based SI parameter value for the prior time 
interval [20]. This step accounts for inter-patient variability by adapting the model estimate of 
patient response to insulin [12].  
2. All possible insulin rates are assessed, based on a minimum insulin rate (0 U/h), a 0.5 U/h 
insulin rate increment and a maximum insulin rate (𝑢𝑚𝑎𝑥), of the current insulin rate + 2U/h 
up to a maximum of 6U/h. Note that the insulin rate of 0.5 U/h is not considered due to its 
small size. Thus, possible insulin rates are 0, 1, 1.5, 2…6 U/h. 
However, in two specific cases, no insulin is required. First, when the current BG level is 
lower than 90 mg/dL; second, when the current BG value is more than 18 mg/dL below the 5th 
percentile expected from the last controller intervention.  
3. For each control interval (2 and 3 hours), the glycemic outcomes of all possible insulin 
interventions (defined in Step 2) are assessed. Only interventions that predicted a maximum 
risk of 5% or less for BG < 90 mg/dL, for safety from moderate (< 60 mg/dL) or severe (< 40 
mg/dL) hypoglycemia [9], are considered feasible. More precisely, the assessment of each 
possible insulin intervention includes 3 phases: 
a) The stochastic model [11] provides a distribution of possible SI parameter values for the 
next 2 (or 3) hours, based on the current SI value (identified in Step 1). This phase 
accounts for the intra-patient variability typically observed in critically ill patients. 
b) The 5th and the 50th (median) percentile BG outcome predictions (𝐵𝐺5𝑡ℎ and 𝐵𝐺50𝑡ℎ 
respectively) are calculated using the insulin-glucose system model and using the 95th and 
50th (median), respectively, percentile expected SI values obtained from Phase (a). The 
𝐵𝐺5𝑡ℎ value illustrates the possible BG spread towards hypoglycemia due to intra-patient 
variability. 
c) Hypoglycemic risk is assessed from the 5th percentile BG value to restrict the forecasted 
risk of BG < 90 mg/dL to a 5% level. Thus 𝐵𝐺5𝑡ℎ ≥ 90 mg/dL must be true for the insulin 
intervention to be feasible. For each time interval (2 and 3 hours), the goal is to find the 
insulin rates that put the 5th percentile BG closest to the lower bound of the target range 
(chosen as 100 mg/dL for this study) to maximize overlap of the outcome BG range with 
the desired target range. Additionally, 𝐵𝐺50𝑡ℎ< 140 mg/dL is required for 3-hourly 
measurements, otherwise, only a 2-hour interval is offered.  
4. The insulin intervention associated with the longest feasible time interval for the next BG 
measurement is selected to minimize workload. 
Step 4 was changed for control of Patients 4 to 10 to allow nurses greater freedom. When 3-hourly 
measurements were available, three options were offered: 
a) 2-hourly measurement, and insulin rate forecasted to achieve closest BG to target after 2 
hours (𝑢1)  
b) 3-hourly measurement and insulin rate forecasted to achieve closest BG to target after 3 
hours (𝑢2). Only patients 1-3 received this option; 
c) 3-hourly measurement and insulin rate using the lesser of the 2-hourly or 3-hourly insulin 
rates (min(𝑢1,𝑢2)). 
By default, the controller would have chosen option (b), if available. The change to Step 4 enabled 
greater nursing flexibility and choice that better reflects STAR framework usage elsewhere [21] and 
made the system more user friendly. 
The SL2 protocol was characterized by two glycemic bands (Figure 2): the 100-140 mg/dL target band 
and the range of glycemic outcomes due to insulin sensitivity variability (Step 3.b). The controller 
aimed to maximize the overlap between these two bands, subject to the 5th percentile BG ≥ 90 mg/dL.  
 
2.2. Stochastic Model 
The stochastic model used with STAR described the hourly changes in insulin sensitivity to improve 
assessment of the patient’s insulin response (Appendix A-2). It was based on clinically observed 
insulin sensitivity variations in ICU populations [11]. The first pilot STAR-Liege trial (SL1) showed 
that post-operative cardiac surgery patients were significantly more variable in their insulin sensitivity 
(SI) than expected during the first post-operative hours [13]. In a final major difference from the first 
pilot trials in Liege, the stochastic model used in this study directly accounts for this variability by 
using clinical data specific to cardiac-surgery patients and for the first days of stay. More precisely, it 
combined the data of cardiac surgery patients from the SPRINT study [5] with the data of all the 
patients of the Glucontrol study [22], to create a more cohort-specific stochastic model that was unique 
to this patient group and study. 
 
2.3. Clinical Trial and Patients 
The SL2 protocol was tested in November and December 2010 at the CHU in Liège, Belgium. Each 
pilot trial was 24 hours long. The clinical trial included 9 patients from the hospital’s intensive care 
unit, 3 patients (Patients 2, 5 and 9) were in the first 48 hours post-surgery. Initially, patients were 
recruited if they had two consecutive blood glucose levels > 145 mg/dL. In practice, clinicians also 
included highly glycemically variable patients (Patients 1, 2 and 5). The clinician stopped patient 2 
after 7 hours due to the diagnosis of pancreatic disease. Table 1 shows the patient details and per-
patient control information. The Ethics Committee of the Medical Faculty of the University of Liege 
(Liege, Belgium) granted approval for this trial and the audit, analysis and publication of these data. 
For each patient, the trial started with a BG measurement made by nursing staff using a bedside 
glucometer (Accu-Check Inform, Roche Diagnostics, Mannheim, Germany) or a blood gas analyzer 
(RAPIDPoint 500 Systems, Siemens, Munich, Germany), depending on availability. This 
measurement was input to the computer and the controller calculated a new insulin infusion rate, 
which was then used by the nurse on the insulin infusion pumps. This clinical process is illustrated in 
Figure 3. 
 
2.4. Analyses 
Results are compared to the prior and subsequent 24 hours of hospital control to assess performance 
and safety versus typical hospital control. Results are also assessed compared to SL1 to determine if 
the goals of reduced workload with no compromise on performance or safety were achieved. In this 
study, glycemic variability refers to the spread of BG values across the cohort that could be illustrated 
by the slope of the BG cumulative density function (CDF) or as the interquartile range.   
3. RESULTS 
Clinical results are summarized in Tables 2 to 4 and in Figures 4 and 5. A total of 91 measurements 
were taken over 194 hours, averaging one measurement every 2.1 hours (~11/day). BG levels were 
relatively tightly distributed, as evidenced by the interquartile range (IQR) range of 33.6 mg/dL (25th – 
75th percentile: 117.2 - 150.8 mg/dL) in Table 2 for the cohort and by the IQR for per-patient median 
values across patients in Table 3. The percentage of BG measurements within the 100-140 mg/dL 
target band was 54.9% indicating that the control was tight in this band, as illustrated by the steep 
slope of BG cumulative density function (CDF) for the whole cohort in Figure 4. A total of 40.7% of 
the BG measurements were ≥ 140 mg/dL primarily due to high initial BG values and short 24-hour 
trials. The remaining 4.4% of measurements (4 measurements) had BG < 100 mg/dL. There were no 
severe hypoglycemic events (BG < 40 mg/dL) and the minimum recorded BG was 70 mg/dL (Patient 
7). Hence, while STAR forecasted a maximum risk of 5% for BG < 90 mg/dL by design, clinical 
results show only 3.3%. 
For context, BG results are compared to 24-hour pre-trial and 24-hour post-trial BG results of the 
same nine patients so that each patient acts as their own control. Table 2 shows that SL2 provided 
better glycemic control compared to the pre-trial period, with 54.9% of BG in the clinically desired 
band (100-140 mg/dL), instead of 10.9%. This improved control was associated with reduced high BG 
levels (from 19.6% to 7.7% of BG ≥ 180 mg/dL) and significantly reduced low BG levels (from 10.9 
% to 1.1% of BG < 80 mg/dL). SL2 did not shift BG levels towards a desired glycemic band, but 
instead gathered BG levels in a range, as illustrated by the steeper slopes of the BG CDF in Figure 5. 
The 24 hours following STAR were similar, but more variable, as shown in Figure 5. Overall, STAR 
successfully reduced BG levels and variability compared to hospital control, while decreasing low BG 
levels and thus increasing safety. 
Table 5 shows details about interventions when nurse interventions differed from protocol 
recommendations, for insulin rates and/or measurement frequency. Surprisingly, when a 3-hourly 
option was available, nurses did not always choose this option (2-hourly intervention chosen 11 of 16 
cases, 69%, Table5). Figure 4 shows that no insulin was given in 18% of control interventions, and 
that insulin rates varied over the full range allowed. Only 5% of insulin rates were higher than 4 U/h, 
and only Patient 5 received the maximum allowable insulin rate of 6 U/h during the 24-hour trial 
(Table 4). Nurses overrode 23 (12%) of the 194 interventions recommended by the protocol: 8 (35%) 
increased insulin rates and 15 (65%) decreased insulin rates (Table 5). 
As mentioned, nutrition input was left to the attending clinician. Approximately 40% of dextrose rates 
were equal to zero, as five patients received no exogenous dextrose inputs (Patients 3, 4, 6 and 10, 
Table 4). Clinical results show that the patients were each fed very differently. 
Table 2 and Figure 4 show that SL2 achieved somewhat tighter, equally safe control compared to SL1. 
BG levels were similarly distributed (p > 0.05), while the number of measurements was reduced by 
55.6% (p < 0.05). SL2 had slightly lower insulin rates due to the significantly lower exogenous 
glucose administration rates (p < 0.01). 
 
 
 
  
4. DISCUSSION 
The SL2 protocol was primarily designed to reduce nurse workload, while maintaining safety and 
control. Three main changes were made. First, while SL1 was characterized by a specific glycemic 
target of 125 mg/dL, SL2 used a target-to-range approach (target band: 100-140 mg/dL). Second, 
measurement frequency was reduced as only 2-hourly and 3-hourly interventions were used, instead of 
the 1- and 2- hourly interventions during the first trial.  Third, the SL2 protocol had fewer rules (for 
example, it did not adjust nutrition rates), which made the protocol more simple and transparent, and 
its application faster. Additionally, the controller used an improved model of the glucose-insulin 
system [19] and a cohort-specific stochastic model to account for a more variable cardiovascular 
cohort [13]. 
Nurse workload was significantly reduced with the SL2 protocol (2.1 hours between measurements vs. 
1.1 for SL1, p < 0.01). Table 5 shows that nurses sometimes choose 2-hourly interventions (31% of 
time) when a 3-hourly option was available. This result indicates that measurement frequency could 
have been further reduced if nurses chose 3-hourly interventions when available. Hence, nurse 
workload could have been further reduced.  
Nurses overrode insulin rates more often during the SL2 clinical trial than during the SL1 clinical trial. 
This difference can be explained by some “lack of trust” in the recommendations, especially as the 
time interval was longer. Nurses were hesitant to administer more than 3U/h, and were quite resistant 
to insulin rate changes (Table 5). However, 35% of override changes increased insulin over 
recommendations. Table 2 and Figure 5 show that hospital control was less effective and more 
variable than STAR, so this non-compliance may not have improved control. 
SL2 explicitly defined a maximum hypoglycemic risk of 5% of BG < 90 mg/dL. In contrast, SL1 used 
a maximum 5% risk of BG < 72 mg/dL [18]. During the SL1 trial, there were 2.0% of BG < 90 
mg/dL, representing 4 of 205 BG measurements. During the SL2 trial, there were 3 of 91 BG < 90 
mg/dL (3.3%). This percentage (and number) of BG < 90mg/dL are acceptable as it is less than the 
desired maximum of 5% (~ 4-5 BG measurements over 91). Despite less frequent measurement and 
intervention, safety was still ensured, and matched design levels. 
The relatively short length of each trial does not allow long-term statistics on control. However, a 
median 1.8 hours to BG < 140 mg/dL indicates total trial length was sufficient to test safety and 
efficacy compared to SL1. The results justify longer trials for 48 or more hours.  
A main difference between the SL1 and SL2 results was the reduced intervention rate, which can 
increase BG variability in patients whose condition changes rapidly. However, the longer intervals 
allowed the effect of changes in insulin infusion rate to be more clearly observed and identified, 
compared to bolus administration in other uses [21] which act more quickly and can thus be more 
rapidly identified. However, these results indicate no increase in variability or risk as a result.  
Some situations are still not automatically managed by STAR. In particular, small meals may be given 
(Patients 8 and 9, Table 1) which are difficult to estimate. The added estimated exogenous glucose 
content was included in control. However, incomplete consumption and estimated exogenous glucose 
content adds uncertainty, although STAR appeared to manage this issue as well as, or better, than 
normal hospital control. Future efforts need to include this aspect more explicitly. 
Finally, this clinical trial includes only 9 subjects. Longer trials over more patients would provide 
greater certainty to the results. However, it is clear that the goals of reducing workload without 
compromising safety or performance were met. Equally, it is clear that STAR was better than the 
normal hospital protocol. The STAR protocol gathered BG levels around the desired glycemic band, 
reduced high BG levels and improved safety by significantly reducing low BG levels. STAR also 
positively impacted on 24-hour post-trial glycemic results. Hence, STAR also helped stabilizing 
patient condition and helped further patient management.  
  
5. CONCLUSION 
The main objective for these second clinical trials was to reduce clinical workload, while maintaining 
control quality and safety, using a target-to-range approach. Results show that clinical workload was 
reduced by over a factor of 2, while safety was maintained with less frequent measurement and 
intervention compared to prior clinical trial. The results presented thus show that safe, effective 
glycemic control can be achieved for a highly variable cohort with significantly reduced workload 
using a model-based method, where several clinical studies on similar cardiovascular cohorts have had 
excessive hypoglycemia. Moreover, STAR was shown to be safer and tighter than the existing hospital 
control. 
  
List of abbreviations 
BG: blood glucose 
CDF: cumulative density function  
CHU: centre hospitalier universitaire  
ICU: intensive care unit  
IQR: interquartile range  
SI: insulin sensitivity   
SL1: first STAR-Liege (trial) 
SL2: second STAR-Liege (trial) 
SPRINT: specialized relative insulin and nutrition tables 
STAR: stochastic targeted  
TGC: tight glycemic control  
 
  
Competing interests 
The authors declare that they have no competing interests. 
  
Authors’ contribution 
ALC developed the SL2 model-based protocol. SP and KTM conducted the trial and made the 
acquisition of data during the clinical trials. All authors were involved in the analysis and 
interpretation of data. The manuscript was originally drafted by SP, and JGC, but all authors made 
contributions through the entire process, including reading and final approval of this manuscript. 
 
 
 
  
Authors' information 
MSc, Cardiovascular Research Centre, Institut de Physique, Université de Liege, Institut de Physics, 
Allée du 6 Août, 17 (Bât B5), B4000 Liege, Liege, Belgium. 
PhD, Cardiovascular Research Centre, Institut de Physique, Université de Liege, Institut de Physics, 
Allée du 6 Août, 17 (Bât B5), B4000 Liege, Liege, Belgium. 
PhD, Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, 
Christchurch, Private Bag 4800, 8054, New Zealand. 
MSc, Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, 
Christchurch, Private Bag 4800, 8054, New Zealand. 
PhD, Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, 
Christchurch, Private Bag 4800, 8054, New Zealand. 
MD, PhD, Department of Intensive Care, Erasme University Hospital, 808 route de Lennik, B1070 
Brussels, Belgium. 
MB, ChB, Department of Intensive Care, Christchurch Hospital, Christchurch, 8054, New Zealand 
MD, PhD, Department of Intensive Care, CHU, Liege, Belgium. 
 
  
Acknowledgements 
Financial Support: 
− Fonds National de la Recherche Scientifique (F.R.S.-FNRS, Belgium). 
− NZ Foundation for Research Science and Technology (FRST). 
− Department of Mechanical Engineering, Scholarship Grant, University of Canterbury, 
Christchurch, New Zealand. 
  
Figure captions 
Figure 1 – Steps of the STAR-Liege 2 protocol. 
Figure 2 - Overlapping of glycemic target band (green) and stochastic predicted range (blue) with 
𝐵𝐺5𝑡ℎ ≥ 90 mg/dL. 
Figure 3 – Clinical process during glycemic control. 
Figure 4 – Whole cohort cumulative density function (CDF) for BG (left panel), insulin rates (middle 
panel) and exogenous glucose rate (right panel). Results of the STAR-Liege 1 (SL1, green) and 
STAR-Liege 2 (SL2, blue) clinical trials are illustrated. 
Figure 5 – Cumulative density function (CDF) for BG levels for 24-hour pre-trial, during trial and 
post-trial for SL2 pilot trial. Target band bounds (100 mg/dL and 140 mg/dL) are highlight in red. 
 
 
  
Table captions 
Table 1 – Patient demographic and clinical data relevant to control. 
Table 2 – Whole cohort glycemic control results. The 24-hour pre-trial, during pilot trial and post-trial 
glycemic data are summarized for SL2 clinical trial. Whole cohort results for SL1 and SL2 pilot trials 
(+) are compared and p-values were calculated using the Fisher exact test (2-tails) excepted for 
distributions (*) where a Wilcoxon rank sum test for equal medians was used. 
Table 3 – Per-patient glycemic control results during SL2 pilot trial. Statistics are presented as median 
[IQR] when it’s appropriated. 
Table 4 – Individual patient results during SL2 pilot trial. 
Table 5 – Details where nurses overrode STAR recommendations during the SL2 pilot trial. Nurses 
overrode 23 of 91 interventions. (-): Interventions where nurses chose 2-hourly intervention when 3-
hourly intervention is available; (*) interventions where nurses chose 3-hourly intervention when 3-
hourly intervention is available. 
 
 
 
Table 1 
  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 
G
en
er
al
 in
fo
rm
at
io
n Date of birth 22/11/1938 9/09/1938 8/12/1959 11/07/1922 11/12/1938 9/09/1938 5/12/1944 19/05/1951 7/01/1939 
Sex F F M M M F M F F 
Diagnosis Gastro Cardio Trauma Neurological Respiratory Cardio (then pneumonic) Cardio Cardio Cardio 
Diabetic No No No No Unknown No Yes Yes Yes 
Post-surgical days in 
ICU 20 0 4 3 2 8 22 4 2 
C
on
tr
ol
 d
et
ai
ls 
Trial date and  
Start time 
15/12/2010 
17:00 
22/11/2010 
13:10 
22/11/2010 
16:00 
24/11/2010 
14:00 
24/11/2010 
18:00 
30/11/2010 
20:00 
30/11/2010 
17:00 
30/11/2010 
21:00 
15/12/2010 
14:00 
Initial BG (mg/dL) 118 159 164 168 223 125 138 127 155 
Number of nurse 
interventions that 
differed from the 
protocol 
recommendations 
0 1 intervention of 4 interventions 
3 interventions of 
9 interventions  
7 interventions of 
12 interventions 
1 intervention of 
11 interventions 0 
2 interventions of 
11 interventions 
7 interventions of 11 
interventions 
2 interventions of 11 
interventions 
Meals  / / / / / / / 
1/12/2011 (9:45): bread 
(120mL/h during 15min) 
1/12/2011 (12:00): 
vegetables (not taken into 
account) 
1/12/2011 (18:30): bread 
(90mL/h during 15min) 
15/12/2010 (12:00): soup 
(30mL/h during 15min) 
15/12/2010 (19:00): bread, 
cheese, carrots (90mL/h 
during 15min, maybe 
underestimated) 
16/12/2010 (10:00): bread, 
orange, coffee (90mL/h 
during 15min) 
16/12/2010 (12:00): soup, 
vegetables, meat (120mL/h 
during 15min) 
Additional drugs / / / Vasopressor (Noradrenaline) Hydrocortisone / / / / 
Vomiting? No No No No No No No No No 
Notes / 
22/11/10 (20:00): 
trial stopped 
because patient 
had big pancreatic 
illness 
/ / / / / / / 
  
Table 2 
 SL2 clinical data SL1 clinical data p-value 
 Pre 24 hour Pilot trial (+) Post 24 hour Pilot trial (+) SL1 vs. SL2 
Number of patients: 9 9 9 9 / 
Total hours: / 194 h / 215 h / 
Number of BG measurements: 46 91 44 205 / 
BG median [IQR] (mg/dL): 155.5  [124.0 - 171.0] 
134.0  
[117.2 - 150.8] 
136.5  
[115.0 - 159.5] 
136.0  
[122.5 - 158.0] 0.27(*) 
% BG within 80-100 mg/dL 8.7 3.3 6.82 3.4 1.00 
% BG within 100-140 mg/dL 10.9 54.9 43.18 50.7 0.53 
% BG within 140-180 mg/dL 50.0 33.0 36.36 37.1 0.51 
% BG ≥ 180 mg/dL 19.6 7.7 9.09 8.3 1.00 
% BG < 90 mg/dL 19.6 3.3 11.4 2.0 0.44 
% BG < 80 mg/dL 10.9 1.1 4.55 0.5 0.52 
% BG < 40 mg/dL 0.0 0.0 0.0 0.0 1.00 
Number of patients < 40 mg/dL 0 0 0 0 / 
Median insulin rate [IQR] (U/h): / 2.0 [1.0 - 2.5] / 1.5 [0.5 - 3.4] 0.92(*) 
Median glucose rate [IQR] (g/h): / 0.0 [0.0 - 5.4] / 7.4 [2.0 - 11.2] 0.00(*) 
 
 
  
Table 3 
Initial BG (mg/dL): 155.0 [126.5 - 165.0] 
Hours of control: 23.0 [23.0 - 24.0] 
Number of BG measurements: 11.0 [10.5 - 11.0] 
BG median (mg/dL) 137.0 [120.3 - 142.4] 
Median %BG within 80-100 mg/dL: 0.0 [0.0 - 9.1] 
Median %BG within 100-140 mg/dL: 54.5 [43.2 - 68.2] 
Median %BG within 140-180 mg/dL: 36.4 [18.2 - 46.6] 
Median %BG ≥ 180 mg/dL: 0.0 [0.0 - 19.9] 
Time to < 125 mg/dL (h): 6.6 [1.9 - 9.0] 
% patients to < 125 mg/dL: 88.9 
Time to < 140 mg/dL (h): 1.8 [0.0 - 2.6] 
% patients to < 140 mg/dL: 100 
Median insulin rate (U/h): 1.4 [0.2 - 2.6] 
Max insulin rate (U/h): 3.0 [2.9 - 4.0] 
Median glucose rate (g/h): 0.0 [0.0 - 4.7] 
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1 23 11 118 118.0  [112.8 - 135.8] 9.1 72.7 18.2 0 0 0 0 80 0.0 [0.0 - 1.0] 2.0 0.0 [0.0 - 0.0] 
2 7 4 159 163.5  [142.5 - 204.0] 0.0 25.0 50.0 25 0 0 0 126 0.3 [0.0 - 2.1] 4.0 4.5 [0.3 - 4.5] 
3 23 9 164 137.0  [131.0 - 148.0] 0.0 66.7 33.3 0 0 0 0 122 2.0 [2.0 - 2.5] 3.0 0.0 [0.0 - 0.0] 
4 24 12 168 140.5  [130.5 - 146.0] 0.0 50.0 50.0 0 0 0 0 109 2.7 [2.5 - 3.5] 3.5 0.0 [0.0 - 0.0] 
5 23 11 223 148.0  [133.8 - 171.0] 0.0 36.4 45.5 18.2 0 0 0 110 4.0 [2.5 - 4.5] 6.0 5.6 [5.6 - 8.5] 
6 24 11 125 118.0  [107.0 - 125.8] 9.1 72.7 18.2 0 0 0 0 82 0.0 [0.0 - 1.0] 3.0 0.0 [0.0 - 0.0] 
7 23 11 138 138.0  [120.5 - 145.3] 0.0 54.5 36.4 0 9.1 9.1 0 70 2.5 [1.7 - 3.0] 4.0 5.4 [5.4 - 5.4] 
8 23 11 127 134.0  [103.8 - 169.0] 9.1 45.5 36.4 9.1 0 0 0 97 1.0 [0.5 - 1.5] 2.5 0.0 [0.0 - 0.0] 
9 24 11 155 121.0  [109.0 - 176.8] 0.0 54.5 18.2 27.3 0 0 0 103 1.4 [1.0 - 1.9] 3.0 2.0 [2.0 - 2.0] 
  
Table 5 
  Protocol recommandations Nurses interventions  
 Patient 2 Intervention 1 3.5 U/h for 2h 1.5 U/h for 1h  
Patient 3 
Intervention 1 6 U/h for 3h 3 U/h for 2h - 
Intervention 2 3.5 U/h for 3h 2.5 U/h for 3h * 
Intervention 3 3.5 U/h for 3h 3 U/h for 3h * 
Patient 4 
Intervention 1 4.5 U/h for 2h 3.5 U/h for 2h  
Intervention 2 5.5 U/h for 3h 3.5 U/h for 2h - 
Intervention 3 4 U/h for 2h 3.5 U/h for 2h  
Intervention 4 1 U/h for 3h or no insulin for 2h 2 U/h for 2h - 
Intervention 5 4.5 U/h for 2h or 4U/h for 3h 3 U/h for 2h - 
Intervention 6 2 U/h for 2h or 3h or 3 U/h for 3h 2.5 U/h for 2h - 
Intervention 7 4 U/h for 2h 3.5 U/h for 2h  
Patient 5 Intervention 1 5.5 U/h for 2h 4.5 U/h for 2h  
Patient 7 
Intervention 1 1 U/h for 2h or 3h or 1.5 U/h for 3h 1.5 U/h for 2h - 
Intervention 2 No insulin for 2h or 3h 1 U/h for 2h - 
Patient 8 
Intervention 1 1.5 U/h for 2h or 3h 1 U/h for 2h - 
Intervention 2 2 U/h for 2h 1 U/h for 2h  
Intervention 3 2 U/h for 3h or 3 U/h for 2h 1.5 U/h for 2h - 
Intervention 4 No insulin for 2h or 3h 0.5 U/H for 2h - 
Intervention 5 No insulin for 3h 0.5 U/H for 3h * 
Intervention 6 3.5 U/h for 2h or 3h 2.5 U/h for 2h - 
Intervention 7 1.5 U/h for 3h 2 U/h for 3h * 
Patient 9 
Intervention 1 No insulin for 3h 1 U/h for 3h * 
Intervention 2 No insulin for 2h 0.5 U/H for 2h  
 
  
Additional file 1 
File name: PenningS - AdditionalFile1 
File format: pdf 
This file provides the description of the glucose-insulin model. 
  
  
Additional file 2 
File name: PenningS – AdditionalFile2 
File format: pdf 
This file provides the description of the stochastic model. 
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